Substrate for CYPs 3A4 and 3A5. No data pointing to clinical CYP-induction.
Chemical description
Selective 5-HT-antagonist used as prophylaxis or treatment of postoperative nausea and nausea under chemotherapy, 2-9 mg/d perorally or parenterally. Metabolized mainly by CYP3A4. No instances of CYP-induction observed clinically.
Ipnet drug reports
Uneventful use reported in 2 patients with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes